I want to begin this article with a scenario: say sepsis due to MRSA (methicillin-resistant Staphylococcus aureus) is documented by the clinician and ICD-10-CM code A41.02 is captured by the coder. Assume that there are no secondary diagnoses or procedures. This leads to the assignment of MS-DRG (Medicare Severity Diagnosis-Related Group) 872 with a relative weight of 1.0283 and APR-DRG (All Patient Refined Diagnosis-Related Group) 720 with SOI (severity of illness) of 2, ROM (risk of mortality) of 1, and relative weight of 0.7191.
The concepts and algorithms of DRGs are complex. In a similar fashion, the molecular and cellular processes underlying sepsis are complicated. A synopsis of these processes will provide insight into the challenges inherent in managing the protean manifestations of sepsis and will facilitate navigation through the medical record, generation of queries, and dialogue with clinicians, with respect to capturing sepsis as a principal or secondary diagnosis.
Sepsis arises due to a dysregulated immune response. PAMPs (pathogen associated molecular patterns), such as peptidoglycan and lipoteichoic acid (from gram-positive bacteria) and lipopolysaccharide (from gram-negative bacteria) incite the immune system by binding to PRRs (pattern recognition receptors), including TLRs (toll-like receptors) expressed on the surface of macrophages. This leads to pro-inflammatory and anti-inflammatory cytokine cascades with ensuing organ dysfunction and failure characteristic of sepsis, severe sepsis, and septic shock, as well as the SOFA and qSOFA scores.
Associated with these factors is a discussion regarding the administration of antibiotics for the management of sepsis. Depending on the causal organisms and the possibility of multi-drug resistance, different classes of antibiotics are initially prescribed for sepsis and cover a wide range of aerobic, anaerobic, gram-positive, and gram-negative bacteria. Based on culture and sensitivity studies, the regimen can be narrowed to one antibiotic. If the patient’s clinical status does not improve or worsens, new classes of antibiotics should be added to the regimen, or the entire regimen may need to be modified.
There are specific rationale regarding the use of several classes of antibiotics prescribed for sepsis: Zosyn, Vancocin, Avelox, and Flagyl.
Zosyn is comprised of piperacillin and tazobactam. Piperacillin is a fourth-generation ureidopenicillin that contains a β-lactam ring that binds DD-transpeptidase, a penicillin-binding protein. This inhibits cross-linking of peptidoglycans and cell wall synthesis, leading to bacteria cell wall lysis. Several bacteria strains possess β-lactamase, which destroys the β-lactam ring and neutralizes piperacillin. In order to circumvent this problem, tazobactam prevents the degradation of piperacillin by inhibiting the action of β-lactamase.
While Zosyn can treat many types of infections, it has limited efficacy against MRSA (methicillin-resistant Staphylococcus aureus). The mecA gene of MRSA encodes for penicillin-binding protein 2a, which does not bind the β-lactam ring and confers resistance to piperacillin.
This explains why Vancocin (vancomycin) is prescribed with Zosyn. Vancocin is a glycopeptide antibiotic that does not possess a β-lactam ring and destroys MRSA via a mechanism distinct from Zosyn. Vancocin binds the terminal D-alanyl-D-alanine amino acid sequence of NAM (N-acetylmuramic acid) and NAG (N-acetylglucosamine), which comprise the backbone of the cell wall. By preventing the formation of the NAM and NAG polymers, Vancocin disrupts the integrity of the cell wall.
Avelox (moxifloxacin) is a fourth-generation fluoroquinolone that is used effectively against many strains of gram-positive and gram-negative bacteria. Avelox inhibits DNA gyrase and topoisomerase IV. DNA gyrase is an enzyme that relieves the strain caused by helicase, as it unwinds the DNA during bacteria replication. Topoisomerase IV is an enzyme that unlinks DNA following replication and also relieves the strain caused by helicase. Together, DNA gyrase and topoisomerase IV generate double-stranded DNA breaks to relieve the strain of the positive DNA supercoils and therefore allow DNA polymerase to replicate the strands of bacteria DNA. The binding of Avelox to DNA gyrase and topoisomerase IV creates complexes termed “topoisomerase poisons” that cleave the bacterial DNA into fragments, resulting in cell death. Since the mechanism of action of Avelox is distinct from Zosyn and Vancocin, Avelox can target strains of bacteria that may be resistant to Zosyn or Vancocin.
Flagyl (metronidazole) belongs to the nitroimidazole class of antibiotics and can treat sepsis caused by anaerobic bacteria, such as Bacteroides fragilis and Clostridium perfringens. In anaerobic bacteria, Flagyl is reduced by pyruvate: ferredoxin oxidoreductase to free radicals. The free radicals, in turn, cause DNA strand breakage, DNA helix destabilization, and death of anaerobic bacteria. Since the pyruvate-ferredoxin oxidoreductase reaction typically does not take place in aerobic bacteria, Flagyl has minimal effect on aerobic bacteria.
In short, an appreciation of the mechanism of action of different classes of antibiotics can shed light on the complexity in managing sepsis.
Hotly anticipated performance targets and payment amounts for the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model
I often begin my day with an environmental scan. Last week, an article from Becker’s Clinical Leadership caught my eye, “Hospital mortality, infectionrates improve despite
Please log in to your account to comment on this article.
Sepsis sequencing continues to challenge even experienced coding and CDI professionals, with evolving guidelines, documentation gaps, and payer scrutiny driving denials and data inconsistencies. In this webcast, Payal Sinha, MBA, RHIA, CCDS, CDIP, CCS, CCS-P, CCDS-O, CRC, CRCR, provides clear guideline-based strategies to accurately code sepsis, severe sepsis, and septic shock, assign POA indicators, clarify the relationship between infection and organ dysfunction, and align documentation across teams. Attendees will gain practical tools to strengthen audit defensibility, improve first-pass accuracy, support appeal success, reduce denials, and ensure accurate quality reporting, empowering organizations to achieve consistent, compliant sepsis coding outcomes.
Expert presenters Kathy Pride, RHIT, CPC, CCS-P, CPMA, and Brandi Russell, RHIA, CCS, COC, CPMA, break down complex fracture care coding rules, walk through correct modifier application (-25, -57, 54, 55), and clarify sequencing for initial and subsequent encounters. Attendees will gain the practical knowledge needed to submit clean claims, ensure compliance, and stay one step ahead of payer audits in 2026.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
